Tag: Pharma acquisition news
Ironwood Pharmaceuticals to acquire Swiss biotech company VectivBio
Ironwood Pharmaceuticals, a gastrointestinal (GI)-focused healthcare company, has agreed to acquire VectivBio Holding AG, a Switzerland-based biotech company, listed on the Nasdaq, for around $1 ... Read More
Lupin to acquire French generics injectables developer Medisol
Indian pharma company Lupin has agreed to acquire Medisol, a French pharmaceutical company, for an undisclosed price. Established in 2011, Medisol is engaged in developing ... Read More
Astellas Pharma to acquire avacincaptad pegol developer Iveric Bio for $6bn
Japanese pharma company Astellas Pharma has agreed to acquire Nasdaq-listed Iveric Bio in an all-cash deal worth around $5.9 billion with an aim to create ... Read More
Lilly to sell hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals
Eli Lilly and Company (Lilly) has agreed to sell its severe hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals in a deal potentially worth up to $1.07 ... Read More
GSK to acquire Canadian biopharma company BELLUS Health for $2bn
GSK has agreed to acquire BELLUS Health, a Canadian biopharma company, in a deal worth around $2 billion in a move to further bolster its ... Read More
Merck to acquire biotech company Prometheus Biosciences for $10.8bn
Merck has agreed to acquire Prometheus Biosciences, a Nasdaq-listed clinical-stage biotechnology company, in an all-cash deal worth around $10.8 billion, in a move to bolster ... Read More
Eris Lifesciences strikes deal for Dr. Reddy’s cosmetic dermatology brands
Eris Lifesciences has announced the acquisition of nine cosmetic dermatology brands in the Indian market from Dr. Reddy's Laboratories for INR 275 crores in cash. ... Read More
Pfizer to acquire cancer drugmaker Seagen for $43bn in cash
American pharmaceutical and biotechnology company Pfizer has agreed to acquire cancer drugmaker Seagen (formerly Seattle Genetics) for $229 per share or $43 billion in cash, ... Read More
Sesen Bio gets shareholders’ approval for merger with Carisma Therapeutics
Nasdaq-listed Sesen Bio said that its stockholders have approved the previously announced merger deal with Carisma Therapeutics aimed at creating a clinical-stage biotechnology company for ... Read More
Dr. Reddy’s Laboratories to acquire Mayne Pharma’s US retail generics portfolio
Dr. Reddy's Laboratories has agreed to acquire the US generic prescription product portfolio of Mayne Pharma Group, an Australian pharma company, in a deal worth ... Read More
